The Psilocybin Race Just Tightened. The Two Front-Runners Are Not Chasing the Same Patients
A second psilocybin drug has reportedly reached the Food and Drug Administration. Psychedelic Alpha reported Monday that Usona Institute has completed a new drug application for major depressive disorder. Usona declined to comment. Neither the nonprofit nor the agency has confirmed the psilocybin NDA.
The label is years away from your schedule. Your cost base is not. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What was reported | Usona Institute has completed a new drug application for psilocybin in major depressive disorder |
| How firm it is | Reported by Psychedelic Alpha on November 2. Usona declined to comment and FDA has not confirmed it |
| Usona’s indication | Major depressive disorder, the broad diagnosis |
| Compass’s indication | Treatment-resistant depression, a narrower group |
| Compass’s status | Rolling submission underway. The company guided to finishing in the fourth quarter |
| Why speed matters | Both hold a Commissioner’s National Priority Voucher, which targets a one to two month review |
| The trial behind Usona | uAspire, a Phase 3 of 238 adults, primary completion January 5, 2026 |
| What decides your access | The REMS, not the approval. Spravato ships only to certified settings |
Treat the Psilocybin NDA Report as Unconfirmed
The report rests on unnamed sources and the outlet’s own understanding. Usona said nothing. FDA does not discuss pending applications, so no confirmation is coming from that direction either.
What is verifiable is the trial underneath it. Usona runs uAspire, a Phase 3 study of psilocybin in major depressive disorder. ClinicalTrials.gov lists 238 adults enrolled and a primary completion date of January 5, 2026. That is a finished readout and the normal moment to file.
The company also has a completed Phase 2 of 347 adults in the same condition. It tested psilocybin against niacin rather than an inert pill. So the program is real and its timing fits. The paperwork is what remains unverified.
If the report holds, psilocybin would be the second psychedelic in front of the agency. Resilient Pharmaceuticals, formerly Lykos, refiled its MDMA application for post-traumatic stress disorder over the summer.
The Two Front-Runners Are Not Chasing the Same Patients
This is the part that matters most for a clinic and the part the coverage skips.
Usona’s Phase 3 is in major depressive disorder. Compass Pathways is filing COMP360 for treatment-resistant depression, which the company confirmed when FDA granted it a rolling review in April.
Those are very different populations. Treatment-resistant depression generally means a patient has already failed multiple adequate antidepressant trials. Major depressive disorder is the diagnosis itself.
For comparison, Spravato is approved for treatment-resistant depression, and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. A psilocybin cleared for major depressive disorder generally would sit on a broader label than that.
Whoever lands first sets the template for how these products are handled. A broad first label and a narrow first label lead to different build-outs.
Why a Decision Could Come Quickly
Both companies hold a Commissioner’s National Priority Voucher. FDA issued three of them to psychedelic programs in April, to Compass, Usona and Otsuka, which we covered in our report on the priority vouchers.
Compass says the voucher targets a one to two month review once an application is filed. A conventional review runs ten to twelve months. Eli Lilly saw a drug cleared 50 days after submission under the same program this year.
So the gap between filing and a decision is unusually short here. That is the reason a filing report moves the sector at all.
The Timeline Has Already Slipped Once
Worth keeping in view before anyone schedules around this. When the vouchers were issued in April, the FDA commissioner said the first psychedelic approval could arrive by the end of summer 2026.
It is November. Nothing has been approved. Compass guided to finishing its submission in the fourth quarter and expects a commercial launch in the first half of 2027.
Treat every date in this category as an estimate from an interested party. That includes the ones in this article.
A Nonprofit Filing Is Not a Normal Filing
Usona is a nonprofit research organization based in Wisconsin. That is an unusual profile for an organization at the front of an FDA queue, and it bears on when a product would actually reach a clinic.
Approval and availability are separate events. A sponsor still has to manufacture at scale, distribute, run a certification program and support prescribers. Those are commercial jobs, not scientific ones.
Compass is built for that half. It reported $433.3 million in cash on June 30, said it had expanded its commercial readiness capabilities, and expects to launch in the first half of 2027.
So the order of filing may not be the order of availability. Those are two different races, and operators care about the second one.
Usona did host a summit on models of care at its Wisconsin campus this year. Psychedelic Alpha reports that Compass, AbbVie and Otsuka attended, though not what was discussed.
Approval Is Not the Thing That Decides Your Access
A clinic does not get to stock an approved psychedelic because it is approved. The risk evaluation and mitigation strategy decides that, and it is written alongside the application rather than after it.
Psychedelic Alpha reports that Usona is working with FDA on a REMS design, again through unnamed sources. Compass has disclosed that FDA site inspections began in September.
The Spravato precedent is the one to study. We walked through it in who actually hands an approved psilocybin to the patient. Product ships only to certified healthcare settings. A pharmacy cannot send it to a patient, and it must verify the setting before shipping.
If psilocybin inherits that structure, your certification status is the gate. Not your interest, and not your clinical readiness.
What Is Worth Doing Now
Nothing to buy and nothing to announce. There is no approved product, and the leading filing is not confirmed.
The useful work is the part that takes months anyway. Know whether your setting could meet a REMS certification standard, and know which pharmacy would supply you if one existed.
Clinics already running Spravato have most of that answer. We mapped how much the two footprints overlap in our look at Compass, Spravato and our directory data.
Patients searching now can start with our directory of verified ketamine clinics, which is where the approved options sit today.
